Fintel reports that on July 9, 2024, TD Cowen initiated coverage of Exscientia plc - Depositary Receipt () (NasdaqGS:EXAI) with a Buy recommendation.
Analyst Price Forecast Suggests 48.86% Upside
As of July 4, 2024, the average one-year price target for Exscientia plc - Depositary Receipt () is $8.50/share. The forecasts range from a low of $7.07 to a high of $10.50. The average price target represents an increase of 48.86% from its latest reported closing price of $5.71 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Exscientia plc - Depositary Receipt () is 27MM, an increase of 10.39%. The projected annual non-GAAP EPS is -1.67.
What is the Fund Sentiment?
There are 93 funds or institutions reporting positions in Exscientia plc - Depositary Receipt (). This is an increase of 1 owner(s) or 1.09% in the last quarter. Average portfolio weight of all funds dedicated to EXAI is 0.28%, an increase of 1.51%. Total shares owned by institutions increased in the last three months by 1.60% to 31,938K shares. 
The put/call ratio of EXAI is 0.57, indicating a bullish outlook.
What are Other Shareholders Doing?
Softbank Group holds 5,682K shares representing 4.50% ownership of the company. No change in the last quarter.
Laurion Capital Management holds 5,410K shares representing 4.28% ownership of the company. No change in the last quarter.
Baillie Gifford holds 4,574K shares representing 3.62% ownership of the company. In its prior filing, the firm reported owning 4,690K shares , representing a decrease of 2.54%. The firm decreased its portfolio allocation in EXAI by 67.62% over the last quarter.
Platinum Investment Management holds 3,947K shares representing 3.12% ownership of the company. In its prior filing, the firm reported owning 4,088K shares , representing a decrease of 3.59%. The firm decreased its portfolio allocation in EXAI by 14.47% over the last quarter.
Woodline Partners holds 1,656K shares representing 1.31% ownership of the company. In its prior filing, the firm reported owning 1,643K shares , representing an increase of 0.78%. The firm decreased its portfolio allocation in EXAI by 23.88% over the last quarter.
Exscientia Background Information
(This description is provided by the company.)
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia's pipeline of internal and partnered programmes demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
